ANIP ANI PHARMACEUTICALS INC
Nasdaq · SEC CIK 1023024 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $14.87M 41 sales by 12 insiders
- Filings on record
- 320 since 2021-09-10, latest 2026-09-16 16:20
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Lalwani Nikhil | Pres, CEO, Dir | — | $5.05M |
| Walsh Patrick D | Dir | — | $2.32M |
| CAREY STEPHEN P. | SVP, CFO | — | $1.78M |
| Mutz Christopher | HEAD OF RARE DISEASE | — | $1.64M |
| Gassert Chad | SVP - CORP. DEV, STRATEGY | — | $1.31M |
| Davis Krista | SVP, Chief HR Off | — | $918.6K |
| Gutwerg Ori | SVP, GENERICS | — | $621.4K |
| Cook Meredith | SVP, GC, SEC | — | $453.9K |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | — | $393.8K |
| HAUGHEY THOMAS | Dir | — | $161.8K |
Transactions 356
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-30 | 2023-03-28 | ANIP | CAREY STEPHEN P. | SVP AND CFO | F - Tax | $38.62 | -1,420 | 137.5K | -1% | -$54.8K | |
| 2023-03-27 | 2023-03-23 | ANIP | CAREY STEPHEN P. | SVP AND CFO | F - Tax | $37.82 | -4,224 | 138.9K | -3% | -$159.8K | |
| 2023-03-27 | 2023-03-23 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | F - Tax | $37.82 | -17.5K | 250.8K | -7% | -$660.1K | |
| 2023-03-27 | 2023-03-23 | ANIP | Marken James G. | SVP OPS, PROD DEV | F - Tax | $37.82 | -2,452 | 112.7K | -2% | -$92.7K | |
| M | 2023-03-09 | 2023-03-07 | ANIP | Gutwerg Ori | SVP, GENERICS | F - Tax | $44.23 | -2,342 | 34.6K | -6% | -$103.6K |
| M | 2023-03-09 | 2023-03-07 | ANIP | Marken James G. | SVP OPS, PROD DEV | F - Tax | $44.23 | -2,460 | 115.2K | -2% | -$108.8K |
| M | 2023-03-09 | 2023-03-07 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | F - Tax | $44.23 | -1,902 | 38.1K | -5% | -$84.1K |
| M | 2023-03-09 | 2023-03-07 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | F - Tax | $44.23 | -13.7K | 268.3K | -5% | -$604.3K |
| M | 2023-03-09 | 2023-03-07 | ANIP | CAREY STEPHEN P. | SVP AND CFO | F - Tax | $44.23 | -3,503 | 143.1K | -2% | -$154.9K |
| 2023-02-17 | 2023-02-15 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | F - Tax | $45.04 | -1,292 | 39.6K | -3% | -$58.2K | |
| 2023-02-17 | 2023-02-15 | ANIP | Gutwerg Ori | SVP, GENERICS | F - Tax | $45.04 | -1,275 | 36.4K | -3% | -$57.4K | |
| 2022-12-02 | 2022-12-01 | ANIP | Meridian Venture Partners II GP, L.P. | 10% | S - Sale | $38.50 | -200.0K | 2.02M | -9% | -$7.70M | |
| 2022-09-14 | 2022-09-12 | ANIP | Davis Krista | SVP, Chief HR Off | A - Grant | $0.00 | +16.4K | 16.4K | New | $0 | |
| 2022-09-12 | 2022-09-08 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | F - Tax | $37.61 | -3,646 | 282.0K | -1% | -$137.1K | |
| M | 2022-08-16 | 2022-08-12+ | ANIP | Marken James G. | SVP OPS, PROD DEV | S - Sale | $37.25 | -18.1K | 122.8K | -13% | -$673.0K |
| 2022-07-20 | 2022-07-18 | ANIP | Cook Meredith | SVP, GC, SEC | A - Grant | $0.00 | +19.3K | 19.3K | New | $0 | |
| 2022-04-29 | 2022-04-27 | ANIP | NASH DAVID | Dir | A - Grant | $0.00 | +10.0K | 31.7K | +46% | $0 | |
| 2022-04-29 | 2022-04-27 | ANIP | CAREY STEPHEN P. | SVP AND CFO | A - Grant | $0.00 | +11.3K | 146.6K | +8% | $0 | |
| 2022-04-29 | 2022-04-27 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | A - Grant | $0.00 | +33.4K | 285.6K | +13% | $0 | |
| 2022-04-29 | 2022-04-27 | ANIP | HAUGHEY THOMAS | Dir | A - Grant | $0.00 | +10.0K | 40.3K | +33% | $0 | |
| 2022-04-29 | 2022-04-27 | ANIP | Marken James G. | SVP OPS, PROD DEV | A - Grant | $0.00 | +6,644 | 135.7K | +5% | $0 | |
| 2022-04-29 | 2022-04-27 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | A - Grant | $0.00 | +6,476 | 40.9K | +19% | $0 | |
| 2022-04-29 | 2022-04-27 | ANIP | Gutwerg Ori | SVP, GENERICS | A - Grant | $0.00 | +6,476 | 37.6K | +21% | $0 | |
| 2022-04-29 | 2022-04-27 | ANIP | Pera Antonio R | Dir | A - Grant | $0.00 | +10.0K | 29.8K | +51% | $0 | |
| 2022-04-29 | 2022-04-27 | ANIP | Walsh Patrick D | Dir | A - Grant | $0.00 | +10.0K | 63.4K | +19% | $0 | |
| 2022-04-29 | 2022-04-27 | ANIP | Thoma Jeanne | Dir | A - Grant | $0.00 | +10.0K | 29.3K | +52% | $0 | |
| 2022-04-29 | 2022-04-27 | ANIP | Brown Robert E. JR | Dir | A - Grant | $0.00 | +10.0K | 49.0K | +26% | $0 | |
| 2022-04-12 | 2022-04-10 | ANIP | CAREY STEPHEN P. | SVP AND CFO | F - Tax | $29.91 | -4,534 | 135.3K | -3% | -$135.6K | |
| 2022-04-12 | 2022-04-10 | ANIP | Marken James G. | SVP OPS, PROD DEV | F - Tax | $29.91 | -1,878 | 129.1K | -1% | -$56.2K | |
| 2022-04-08 | 2022-04-06 | ANIP | CAREY STEPHEN P. | SVP AND CFO | F - Tax | $29.69 | -912 | 139.9K | -0.6% | -$27.1K | |
| 2022-04-08 | 2022-04-06 | ANIP | Marken James G. | SVP OPS, PROD DEV | F - Tax | $29.69 | -337 | 130.9K | -0.3% | -$10.0K | |
| 2022-03-30 | 2022-03-28 | ANIP | CAREY STEPHEN P. | SVP AND CFO | F - Tax | $28.17 | -1,420 | 140.8K | -1.0% | -$40.0K | |
| 2022-03-30 | 2022-03-28 | ANIP | Marken James G. | SVP OPS, PROD DEV | F - Tax | $28.17 | -524 | 131.3K | -0.4% | -$14.8K | |
| 2022-03-28 | 2022-03-24 | ANIP | Gutwerg Ori | SVP, GENERICS | A - Grant | $0.00 | +19.4K | 31.2K | +165% | $0 | |
| 2022-03-28 | 2022-03-24 | ANIP | Marken James G. | SVP OPS, PROD DEV | A - Grant | $0.00 | +19.9K | 131.8K | +18% | $0 | |
| 2022-03-28 | 2022-03-24 | ANIP | CAREY STEPHEN P. | SVP AND CFO | A - Grant | $0.00 | +33.9K | 142.2K | +31% | $0 | |
| 2022-03-28 | 2022-03-24 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | A - Grant | $0.00 | +100.1K | 252.3K | +66% | $0 | |
| 2022-03-28 | 2022-03-24 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | A - Grant | $0.00 | +19.4K | 34.4K | +130% | $0 | |
| 2022-03-25 | 2022-03-23 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | F - Tax | $27.03 | -17.5K | 152.2K | -10% | -$471.8K | |
| 2022-03-25 | 2022-03-23 | ANIP | Marken James G. | SVP OPS, PROD DEV | F - Tax | $27.03 | -2,452 | 111.9K | -2% | -$66.3K | |
| 2022-03-25 | 2022-03-23 | ANIP | CAREY STEPHEN P. | SVP AND CFO | F - Tax | $27.03 | -4,167 | 108.3K | -4% | -$112.6K | |
| 2022-03-23 | 2022-03-21 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | P - Purchase | $27.69 | +7,224 | 169.7K | +4% | +$200.0K | |
| MI | 2022-03-22 | 2022-03-18+ | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | P - Purchase | $27.51 | +10.0K | 393.2K | +3% | +$275.1K |
| 2022-03-22 | 2022-03-19 | ANIP | TANNENBAUM RENEE P | Dir | A - Grant | $0.00 | +13.3K | 13.3K | New | $0 | |
| 2022-03-22 | 2022-03-21 | ANIP | Walsh Patrick D | Dir | P - Purchase | $27.76 | +5,000 | 53.4K | +10% | +$138.8K | |
| I | 2022-03-21 | 2022-03-17 | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | P - Purchase | $27.65 | +5,000 | 5,000 | New | +$138.2K |
| 2022-03-21 | 2022-03-17 | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | P - Purchase | $27.65 | +5,000 | 18.5K | +37% | +$138.2K | |
| 2022-02-17 | 2022-02-15 | ANIP | Gutwerg Ori | SVP, GENERICS | F - Tax | $40.25 | -1,167 | 11.7K | -9% | -$47.0K | |
| 2022-02-17 | 2022-02-15 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | F - Tax | $40.25 | -1,184 | 14.9K | -7% | -$47.7K | |
| 2021-12-22 | 2021-12-20 | ANIP | Thoma Jeanne | Dir | P - Purchase | $46.47 | +1,072 | 17.8K | +6% | +$49.8K | |
| 2021-12-09 | 2021-12-07 | ANIP | Pera Antonio R | Dir | P - Purchase | $42.26 | +3,000 | 19.7K | +18% | +$126.8K | |
| 2021-12-07 | 2021-12-06 | ANIP | HAUGHEY THOMAS | Dir | P - Purchase | $39.38 | +2,500 | 30.2K | +9% | +$98.5K | |
| I | 2021-11-23 | 2021-11-19 | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | A - Grant | — | +1.33M | 1.33M | New | — |
| 2021-11-23 | 2021-11-19 | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | A - Grant | — | +13.5K | 13.5K | New | — | |
| I | 2021-11-23 | 2021-11-19 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | A - Grant | — | +383.2K | 383.2K | New | — |
| 2021-09-10 | 2021-09-08 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | F - Tax | $28.20 | -2,577 | 162.4K | -2% | -$72.7K |
Purchase Sale Sale after option exercise All abbreviations